STURGIS, S.D. (KOTA) - Alex Usera and Mark Chaplin were elected to the Sturgis City Council in a special election held Tuesday in Sturgis. Usera beat out opponent Ryan Klama in a 69 to 67 vote.

She is survived by her husband, Glenn Sturgis Sr., two sons, Glenn Sturgis Jr., and Alex Sturgis, one daughter, Emily Sturgis all of Port Charlotte. Five sisters, Denise King and Joyce Hesse of ...

ALX Oncology reported positive interim results from a phase 2 study of a combo drug featuring evorpacept. Evorpacept showed great potential in treating gastric/gastroesophageal junction cancer ...

ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ...

ALX Oncology’s phase 2 gastric cancer response rate has weakened. After seeing its CD47 blocker easily beat control over the first half of the trial, the biotech reported a much closer fight in ...

ALX Oncology Holdings Inc. (ALXO, Financials) saw its stock price fall 15.8% to $1.52 as of 2:32 p.m. GMT-5 on Thursday, despite announcing positive updated results from its ASPEN-06 Phase 2 ...

ALX Oncology reports promising Phase 1 results for evorpacept combined with R2 in treating relapsed B-NHL at AACR 2025. Quiver AI Summary. ALX Oncology announced promising results from a Phase 1/2 ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. The drug, called evorpacept, is in a pair of phase 2 trials for ...

During the R&D Day event, ALX Oncology leadership will discuss the mechanistic rationale and clinical data that support further development of evorpacept with anti-cancer antibodies. In addition ...

ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP ...